Cover Image
市場調查報告書

InvivoGen Therapeutics 產品平台分析

InvivoGen Therapeutics - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 307311
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
InvivoGen Therapeutics 產品平台分析 InvivoGen Therapeutics - Product Pipeline Review - 2014
出版日期: 2014年06月30日 內容資訊: 英文 24 Pages
簡介

本報告提供InvivoGen Therapeutics 的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

InvivoGen Therapeutics的基本資料

InvivoGen Therapeutics概要

  • 主要資訊
  • 企業資料

InvivoGen Therapeutics:R&D概要

  • 主要的治療範圍

InvivoGen Therapeutics:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

InvivoGen Therapeutics:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

InvivoGen Therapeutics:藥物簡介

  • PEI-DNA
  • Plasmid Gene Therapy for Chemotherapy-Induced Thrombocytopenia
  • IgA Therapy Project
  • Plasmid Gene Therapy for Cystic Fibrosis

InvivoGen Therapeutics:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

InvivoGen Therapeutics:暫停中的計劃

InvivoGen Therapeutics:總公司和子公司的所地

附錄

圖表一覽

目錄
Product Code: GMDHC05238CDB

Summary

Global Markets Direct's, 'InvivoGen Therapeutics - Product Pipeline Review - 2014', provides an overview of the InvivoGen Therapeutics's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InvivoGen Therapeutics's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of InvivoGen Therapeutics including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of InvivoGen Therapeutics's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the InvivoGen Therapeutics's pipeline products

Reasons to buy

  • Evaluate InvivoGen Therapeutics's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of InvivoGen Therapeutics in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the InvivoGen Therapeutics's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of InvivoGen Therapeutics and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of InvivoGen Therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of InvivoGen Therapeutics and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • InvivoGen Therapeutics Snapshot
    • InvivoGen Therapeutics Overview
    • Key Information
    • Key Facts
  • InvivoGen Therapeutics - Research and Development Overview
    • Key Therapeutic Areas
  • InvivoGen Therapeutics - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • InvivoGen Therapeutics - Pipeline Products Glance
    • InvivoGen Therapeutics - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • InvivoGen Therapeutics - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • InvivoGen Therapeutics - Drug Profiles
    • PEI-DNA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Plasmid Gene Therapy for Chemotherapy-Induced Thrombocytopenia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IgA Therapy Project
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Plasmid Gene Therapy for Cystic Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • InvivoGen Therapeutics - Pipeline Analysis
    • InvivoGen Therapeutics - Pipeline Products by Target
    • InvivoGen Therapeutics - Pipeline Products by Route of Administration
    • InvivoGen Therapeutics - Pipeline Products by Molecule Type
    • InvivoGen Therapeutics - Pipeline Products by Mechanism of Action
  • InvivoGen Therapeutics - Dormant Projects
  • InvivoGen Therapeutics - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • InvivoGen Therapeutics, Key Information
  • InvivoGen Therapeutics, Key Facts
  • InvivoGen Therapeutics - Pipeline by Indication, 2014
  • InvivoGen Therapeutics - Pipeline by Stage of Development, 2014
  • InvivoGen Therapeutics - Monotherapy Products in Pipeline, 2014
  • InvivoGen Therapeutics - Phase I, 2014
  • InvivoGen Therapeutics - Preclinical, 2014
  • InvivoGen Therapeutics - Discovery, 2014
  • InvivoGen Therapeutics - Pipeline by Target, 2014
  • InvivoGen Therapeutics - Pipeline by Route of Administration, 2014
  • InvivoGen Therapeutics - Pipeline by Molecule Type, 2014
  • InvivoGen Therapeutics - Pipeline Products by Mechanism of Action, 2014
  • InvivoGen Therapeutics - Dormant Developmental Projects,2014

List of Figures

  • InvivoGen Therapeutics - Pipeline by Top 10 Indication, 2014
  • InvivoGen Therapeutics - Pipeline by Stage of Development, 2014
  • InvivoGen Therapeutics - Monotherapy Products in Pipeline, 2014
  • InvivoGen Therapeutics - Pipeline by Top 10 Target, 2014
  • InvivoGen Therapeutics - Pipeline by Top 10 Route of Administration, 2014
  • InvivoGen Therapeutics - Pipeline by Top 10 Molecule Type, 2014
  • InvivoGen Therapeutics - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top